Business Context and Reporting Period
This Form 8-K reports on the results of a Special Meeting of Stockholders held by Moleculin Biotech, Inc. on April 15, 2026. The company is incorporated in Delaware and its common stock trades on the NASDAQ under the symbol MBRX.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and voting outcomes.
Material Changes and Voting Results
As of the record date (February 20, 2026), there were 4,933,110 shares outstanding. A quorum was established with 2,382,989 shares present. The voting results for the three proposals were as follows:
- Proposal 1 (Nasdaq Warrant Approval): Approved. Stockholders approved the issuance of up to 6,367,956 shares upon exercise of warrants issued on February 20, 2026. Votes: 854,036 For, 211,394 Against, 7,489 Abstain.
- Proposal 2 (Name Change): Not Approved. The proposal to change the company name from "Moleculin Biotech, Inc." to "Moleculin Inc." failed because it did not receive a majority of the outstanding shares on the record date. Votes: 2,015,174 For, 82,841 Against, 284,974 Abstain.
- Proposal 3 (Adjournment): Approved. Stockholders approved an adjournment to solicit additional proxies if necessary for the other proposals. Votes: 616,186 For, 169,854 Against, 286,879 Abstain.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, or specific risk factors beyond the standard disclosure that the name change proposal failed to meet the required voting threshold. The approval of the adjournment indicates the company may continue efforts to secure votes for the name change or warrant proposal in the future.
Investor Verification Checklist
- Verify the specific terms and exercise price of the warrants approved under Proposal 1.
- Confirm the current corporate name remains "Moleculin Biotech, Inc." following the rejection of Proposal 2.
- Monitor future filings for updates on the adjournment and any subsequent attempts to pass the name change proposal.
- Review the definitive proxy statement filed on March 9, 2026, for detailed descriptions of the proposals.